NVH Medicinal

NVH Medicinal is a biotechnology company based in Dijon that was founded in 2008. The company's mission is to address pathologies related to collagen deficiency by developing products derived from collagen, the most abundant protein in the body. These products aim to tackle a range of diseases, including aging, cardiovascular, inflammatory, neurological, fibrosis, cancer, and rare diseases. NVH's ambition is to establish itself as an innovative player in collagen-related disease treatment and become a global leader in the development, production, and commercialization of a new family of recombinant proteins derived from collagen, called collagen analogs or synthetic collagens that hold promise for treating various ailments. As of now, there is no public information available about NVH Medicinal's last investment or the involved investors. However, the company's commitment to addressing critical medical needs through biotechnological advancements makes it an intriguing prospect for potential venture capital interest. With its focused approach on collagen deficiency-related diseases and advanced biotechnological solutions, NVH Medicinal presents an attractive opportunity for investors seeking to support innovative advancements in the biotechnology industry.